Peptide Schedule
CerebrolysinSmall moleculeNo amino acid sequence. Icon reflects category theme only.Cerebrolysin Dosage Calculator
Cerebrolysin is a porcine brain-derived peptide preparation manufactured by EVER Neuro Pharma.
1,076mcg · Daily
Summary: Add 0mL BAC water to your 1076mg vial. Draw to < 0.1 units on a U-100 syringe for a 1,076mcg dose. This vial will last 0 doses.
Cycle Planner
Cerebrolysin Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~2-4 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Cerebrolysin Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1076mg | Daily |
| Moderate | 2152mg | Daily |
| Aggressive | 4304mg | Daily |
Note: Porcine brain-derived peptide preparation (215.2 mg/mL). Pre-filled solution — no reconstitution needed. Administer IM (up to 5 mL) or IV (above 5 mL). Run as a 10-21 day course with 3-6 month breaks. NOT FDA-approved in the US but approved in 40+ countries. Morning dosing preferred.
About Cerebrolysin
Cerebrolysin is a porcine brain-derived peptide preparation manufactured by EVER Neuro Pharma. It contains a standardized mixture of low-molecular-weight neuropeptides (approximately 25% by weight) and free amino acids (approximately 75%) obtained through controlled enzymatic proteolysis of purified porcine brain proteins. The active peptide fraction includes fragments that mimic the activity of endogenous neurotrophic factors such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF). Cerebrolysin has been used clinically in over 40 countries — primarily in Europe, Asia, and Latin America — for the treatment of acute ischemic stroke, traumatic brain injury, Alzheimer's disease, and vascular dementia. It is not FDA-approved in the United States and remains classified as a research compound in that market. Multiple randomized, double-blind, placebo-controlled trials have demonstrated improvements in cognitive function, global clinical outcomes, and neurological recovery scores in patients with mild-to-moderate Alzheimer's disease and post-stroke populations. The preparation is administered by intramuscular injection (for volumes up to 5 mL) or by slow intravenous infusion (for volumes above 5 mL, diluted in standard saline). Treatment protocols typically run 10 to 21 consecutive days, followed by rest periods of 3 to 6 months. Courses may be repeated two to four times per year depending on clinical response. Within the nootropic and biohacking community, Cerebrolysin is primarily sought for its neurotrophic and neuroprotective properties — particularly its ability to increase BDNF, promote synaptogenesis, and support neuronal survival under conditions of oxidative stress or age-related decline.